Results 151 to 160 of about 197,418 (252)

Short-acting β₂-agonist prescription patterns and clinical outcomes in Malaysia: A nationwide cohort of the SABINA III study. [PDF]

Malays Fam Physician, 2023
Ban AY, Vengadasalam P, Taher SW, Mohd Zim MA, Sirol Aflah SS, Daut UN, Hyder Ali IA, Pereirasamy L, Omar A, Ibrahim A, Mohd Tarekh NA, Chan SK, Ali N, Mohd Isa NA, Hussain H, Abdul Karim N, Raja Gopal V, Chiam SY, Beekman MJHI.   +18 more
europepmc   +1 more source

A Real‐World Controlled Multicentre Study Evaluating the Association Between Benralizumab Therapy and Major Outcomes in Severe Asthma

Clinical &Experimental Allergy, EarlyView.
Among patients with severe eosinophilic asthma, benralizumab was associated with greater improvements in asthma outcomes—such as improved asthma control, quality of life and remission rates—compared to biologic‐naïve patients. ABSTRACT Background Real‐world data on benralizumab in patients with severe eosinophilic asthma–while controlling for ...
Dennis Thomas, Vanessa M. McDonald, Gijo Thomas, Joy Lee, Li Ping Chung, Matthew Peters, Shakti D. Shukla, Yuto Hamada, Erin S. Harvey, Michael Fricker, Hayley See, Rejoy Sabin Thomas, Claude S. Farah, Andrew Gillman, Constance H. Katelaris, Gregory P. Katsoulotos, David Langton, Peter G. Middleton, Paul Reynolds, Janet Rimmer, Francis Thien, Stephen Vincent, John W. Upham, Peter G. Gibson   +23 more
wiley   +1 more source

Effect of long-acting β2-agonist and corticosteroid combination treatment on parotid glands of rats (histological and immunohistochemical study). [PDF]

BMC Oral Health
Nabil LM, Riad D.
europepmc   +1 more source

Long Non‐Coding RNA, Like NEAT1 and MALAT1, in Asthma: Mechanisms and Therapeutic Potential

Clinical &Experimental Allergy, EarlyView.
Long non‐coding RNA, like NEAT1 and MALAT1, is emerging as a regulator of asthma‐related inflammation, airway remodelling, viral responses and cell death pathways, and are promising targets for future therapeutics. ABSTRACT Asthma affects millions worldwide. Long non‐coding RNA (lncRNA) are emerging as important factors in the pathophysiology of asthma
Ashlyn Poole, Ingrid Laing, Ryan Mead‐Hunter, Peter Le Souef, Guicheng Zhang   +4 more
wiley   +1 more source

The association between blood eosinophil count and clinical outcomes during inhaled corticosteroid/long-acting β2-agonist treatment in stable-phase chronic obstructive pulmonary disease: A retrospective cohort analysis. [PDF]

Medicine (Baltimore)
Liu Y, Chen S.
europepmc   +1 more source

Short-acting β₂ -agonist use and asthma exacerbations in Swedish children: A SABINA Junior study. [PDF]

Pediatr Allergy Immunol, 2022
Melén E, Nwaru BI, Wiklund F, de Fine Licht S, Telg G, Maslova E, van der Valk RJP, Tran TN, Ekström M, Janson C.   +9 more
europepmc   +1 more source

Nephroprotective Effects of the Dual GCGR/GLP‐1R Agonist Survodutide in Hypertension‐Accelerated Diabetic Kidney Disease

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Survodutide is a novel long‐acting dual glucagon (GCGR)/glucagon‐like peptide‐1 (GLP‐1R) receptor agonist currently in phase‐3 clinical development for the treatment of people living with obesity and metabolic dysfunction‐associated steatohepatitis.
Alexander Hamilton, Louise Thisted, Maria Ougaard, Max Hahn, Kasper Andersen, Johanna Perens, Robert Augustin, Besnik Bajrami, Wolfgang Rist, Michael Christensen, Henrik H. Hansen, Thomas Klein   +11 more
wiley   +1 more source

β₂-agonist toxicity in pregnancy causing troponin elevation and fetal distress. [PDF]

BMJ Case Rep
Stobie W, Joseph F.
europepmc   +1 more source

Short-acting β₂-agonist prescription patterns for asthma management in the SABINA III primary care cohort. [PDF]

NPJ Prim Care Respir Med, 2022
Price D, Hancock K, Doan J, Taher SW, Muhwa CJ, Farouk H, Beekman MJHI.   +6 more
europepmc   +1 more source

Novel targets in headache: A narrative review

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objectives/Background This narrative review summarizes novel applications for the use of calcitonin gene‐related peptide (CGRP)‐targeted therapies that go beyond migraine, the latest updates with respect to targeting pituitary adenylate cyclase‐activating peptide (PACAP) as therapeutic in migraine, as well as exploring other more recently ...
Adriana Della Pietra, Peter J. Goadsby, Carolina Oldoni, Stephen Silberstein, Fred Cohen, Simon Akerman   +5 more
wiley   +1 more source